 - High-risk neuroblastoma with at least ONE of the following: 1. Recurrentprogressive disease. 2. Refractory disease i.e. less than a partial response to frontline therapy. No biopsy is required for eligibility for study. 3. Persistent disease after at least a partial response to frontline therapy i.e. patient has had at least a partial response to frontline therapy but still has residual disease by MIBG, CTMRI, or bone marrow. Patients in this category are REQUIRED to have a biopsy of at least one residual site demonstrating viable neuroblastoma. 